CU20110070A6 - METHOD FOR TREATING ENDOMETRIOSIS WITHOUT DECREASING BONE DENSITY - Google Patents
METHOD FOR TREATING ENDOMETRIOSIS WITHOUT DECREASING BONE DENSITYInfo
- Publication number
- CU20110070A6 CU20110070A6 CU20110070A CU20110070A CU20110070A6 CU 20110070 A6 CU20110070 A6 CU 20110070A6 CU 20110070 A CU20110070 A CU 20110070A CU 20110070 A CU20110070 A CU 20110070A CU 20110070 A6 CU20110070 A6 CU 20110070A6
- Authority
- CU
- Cuba
- Prior art keywords
- bone density
- pharmaceutical composition
- endometriosis
- negative influence
- acetate
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 3
- 230000037182 bone density Effects 0.000 title abstract 3
- 230000003247 decreasing effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010003497 Asphyxia Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 abstract 1
- 229960000978 cyproterone acetate Drugs 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica para el tratamiento de endometriosis sin reducir la densidad ósea contiene un gestágeno con eficacia antiandrogénica, con preferencia 17alfa-cianometil-17-beta-hidroxiestra-4,9-dien-3-ona (dienogest), acetato de ciproterona o acetato de cloromadinona en una dosis diaria que es como máximo el doble de la dosis inhibidora de la ovulación, junto con uno o varios excipientes/portadores farmacéuticamente aceptables. La composición farmacéutica según la invención produce tanto la reducción de la endometriosis como también la ausencia de influencia negativa sobre el metabolismo óseo y de la densidad ósea y al mismo tiempo puede mantener en una medida tolerable los efectos colaterales conocidos de los medicamentos convencionales (por ejemplo, sofocaciones, acné, influencia negativa del perfil lipídico). La composición farmacéutica es por ello apropiada para la aplicación a largo plazo.A pharmaceutical composition for the treatment of endometriosis without reducing bone density contains a gestagen with antiandrogenic efficacy, preferably 17alpha-cyanomethyl-17-beta-hydroxystetra-4,9-dien-3-one (dienogest), cyproterone acetate or acetate of chloromadinone in a daily dose that is at most double the ovulation inhibitor dose, together with one or more pharmaceutically acceptable excipients / carriers. The pharmaceutical composition according to the invention produces both the reduction of endometriosis as well as the absence of negative influence on bone metabolism and bone density and at the same time can maintain to a tolerable extent the known side effects of conventional medications (for example , suffocations, acne, negative influence of the lipid profile). The pharmaceutical composition is therefore appropriate for long-term application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20110070A CU20110070A6 (en) | 2011-03-29 | 2011-03-29 | METHOD FOR TREATING ENDOMETRIOSIS WITHOUT DECREASING BONE DENSITY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20110070A CU20110070A6 (en) | 2011-03-29 | 2011-03-29 | METHOD FOR TREATING ENDOMETRIOSIS WITHOUT DECREASING BONE DENSITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20110070A6 true CU20110070A6 (en) | 2011-12-28 |
Family
ID=45508726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20110070A CU20110070A6 (en) | 2011-03-29 | 2011-03-29 | METHOD FOR TREATING ENDOMETRIOSIS WITHOUT DECREASING BONE DENSITY |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU20110070A6 (en) |
-
2011
- 2011-03-29 CU CU20110070A patent/CU20110070A6/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001292A1 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| AR080912A1 (en) | ORAL SOLID DOSAGE FORMS WITH VERY LOW DOSE FOR HRT | |
| MX2020001550A (en) | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCER. | |
| MX392839B (en) | SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT. | |
| PE20141906A1 (en) | ESKETAMINE FOR THE TREATMENT OF DEPRESSION REFRACTORY TO TREATMENT OR RESISTANT TO TREATMENT | |
| CR20160200A (en) | COMBINATIONS OF HISTONE DEACETILASE INHIBITORS AND IMMUNOMODULATING DRUGS | |
| UY35624A (en) | USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE | |
| MX2016015437A (en) | COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101. | |
| DOP2013000131A (en) | COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND A MEK INHIBITOR | |
| BR112018003836A2 (en) | btk inhibitor combinations to treat multiple myeloma | |
| CO2019000604A2 (en) | Vaginal composition comprising a combination of estrogen and vitamin D | |
| UY32650A (en) | MEDICINAL ORAL ADMINISTRATION CONTAINING AT LEAST ONE STEROGEN AND / OR AT LEAST A GESTAGEN AND AT LEAST A PROBIOTIC BACTERIA CEPA | |
| ECSP099482A (en) | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS | |
| MX2022000394A (en) | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer. | |
| UY35890A (en) | USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE | |
| GT200900296A (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVE AGENT. | |
| CU20110070A6 (en) | METHOD FOR TREATING ENDOMETRIOSIS WITHOUT DECREASING BONE DENSITY | |
| MX370451B (en) | Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy. | |
| CU20090116A7 (en) | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS | |
| AR116592A1 (en) | TREATMENT OF PRIMARY BILIARY CHOLANGITIS AND PRIMARY SCLEROSING CHOLANGITIS WITH BARICITINIB | |
| CL2010001230A1 (en) | Method for inhibiting melanogenesis comprising administering a steroidal compound; pharmaceutical composition; topical formulation, useful in the treatment of a disease or condition that involves melanogenesis. | |
| UA54591U (en) | Method for treating varicose | |
| UY31095A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSIVE AGENT AND AN ANTI-VIRAL AGENT | |
| ECSP109996A (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTIMICROBIAL AGENT AND A SELECTIVE INHIBITING AGENT OF THE ENCEPHALINASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF THE ACUTE BACTERIAL DIARRHEA | |
| CU20090062A7 (en) | USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID |